EORTC /LinkedIn
Aug 4, 2025, 14:30
EORTC Announces the First Patient In for the EORTC-2148 MRD Study
EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“We’re proud to announce the First Patient In (FPI) for the EORTC-2148 MRD study, exploring whether a simple blood test can detect cancer recurrence earlier than traditional methods. This marks a major step forward in personalised cancer care and ctDNA research.
Read the full article here:
The MRD project is supported by Guardant Health and League Against Cancer.
The SPECTA platform is supported by Alliance Healthcare.”
More posts featuring European Organisation for Research and Treatment of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 4, 2025, 14:30
Aug 4, 2025, 13:47
Aug 4, 2025, 13:24
Aug 4, 2025, 13:01
Aug 4, 2025, 12:30
Aug 4, 2025, 12:06
Aug 4, 2025, 11:31